1
|
Santucci KL, Baust JM, Snyder KK, Van Buskirk RG, Baust JG. Dose Escalation of Vitamin D 3 Yields Similar Cryosurgical Outcome to Single Dose Exposure in a Prostate Cancer Model. Cancer Control 2018; 25:1073274818757418. [PMID: 29480024 PMCID: PMC5933822 DOI: 10.1177/1073274818757418] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Vitamin D3 (VD3) is an effective adjunctive agent, enhancing the destructive effects of freezing in prostate cancer cryoablation studies. We investigated whether dose escalation of VD3 over several weeks, to model the increase in physiological VD3 levels if an oral supplement were prescribed, would be as or more effective than a single treatment 1 to 2 days prior to freezing. PC-3 cells in log phase growth to model aggressive, highly metabolically active prostate cancer were exposed to a gradually increasing dose of VD3 to a final dose of 80 nM over a 4-week period, maintained for 2 weeks at 80 nM, and then exposed to mild sublethal freezing temperatures. Results demonstrate that both acute 24-hour exposure to 80 nM VD3 and dose escalation resulted in enhanced cell death following freezing at −15°C or colder, with no significant differences between the 2 exposure regimes. Apoptotic analysis within the initial 24-hour period postfreeze revealed that VD3 treatment induced both caspase 8- and 9-mediated cell death, most notably in caspase 8 at 8-hour postfreeze. These results indicate that both the intrinsic and extrinsic apoptotic pathways are involved in VD3 sensitization prior to freezing. Additionally, both acute and gradual dose escalation regimes of VD3 exposure increase prostate cancer cell sensitivity to mild freezing. Importantly, this study expands upon previous reports and suggests that the combination of VD3 and freezing may offer an effective treatment for both slow growth and highly aggressive prostate cancers.
Collapse
Affiliation(s)
- Kimberly L Santucci
- 1 Department of Biological Sciences, State University of New York at Binghamton, Binghamton, NY, USA.,2 Institute for Biomedical Technology, State University of New York at Binghamton, Binghamton, NY, USA.,3 CPSI Biotech, Owego, NY, USA
| | - John M Baust
- 2 Institute for Biomedical Technology, State University of New York at Binghamton, Binghamton, NY, USA.,3 CPSI Biotech, Owego, NY, USA
| | - Kristi K Snyder
- 2 Institute for Biomedical Technology, State University of New York at Binghamton, Binghamton, NY, USA.,3 CPSI Biotech, Owego, NY, USA
| | - Robert G Van Buskirk
- 1 Department of Biological Sciences, State University of New York at Binghamton, Binghamton, NY, USA.,2 Institute for Biomedical Technology, State University of New York at Binghamton, Binghamton, NY, USA.,3 CPSI Biotech, Owego, NY, USA
| | - John G Baust
- 1 Department of Biological Sciences, State University of New York at Binghamton, Binghamton, NY, USA.,2 Institute for Biomedical Technology, State University of New York at Binghamton, Binghamton, NY, USA
| |
Collapse
|
2
|
Goel R, Anderson K, Slaton J, Schmidlin F, Vercellotti G, Belcher J, Bischof JC. Adjuvant approaches to enhance cryosurgery. J Biomech Eng 2009; 131:074003. [PMID: 19640135 DOI: 10.1115/1.3156804] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Molecular adjuvants can be used to enhance the natural destructive mechanisms of freezing within tissue. This review discusses their use in the growing field of combinatorial or adjuvant enhanced cryosurgery for a variety of disease conditions. Two important motivations for adjuvant use are: (1) increased control of the local disease in the area of freezing (i.e., reduced local recurrence of disease) and (2) reduced complications due to over-freezing into adjacent tissues (i.e., reduced normal functional tissue destruction near the treatment site). This review starts with a brief overview of cryosurgical technology including probes and cryogens and major mechanisms of cellular, vascular injury and possible immunological effects due to freeze-thaw treatment in vivo. The review then focuses on adjuvants to each of these mechanisms that make the tissue more sensitive to freeze-thaw injury. Four broad classes of adjuvants are discussed including: thermophysical agents (eutectic forming salts and amino acids), chemotherapuetics, vascular agents and immunomodulators. The key issues of selection, timing, dose and delivery of these adjuvants are then elaborated. Finally, work with a particularly promising vascular adjuvant, TNF-alpha, that shows the ability to destroy all cancer within a cryosurgical iceball is highlighted.
Collapse
Affiliation(s)
- Raghav Goel
- Department of Biomedical Engineering, University of Minnesota, Minneapolis, MN 55455, USA
| | | | | | | | | | | | | |
Collapse
|
3
|
Beemster PW, Lagerveld BW, Witte LPW, de la Rosette JJMCH, Pes MPL, Wijkstra H. The Performance of 17-gauge Cryoprobes In Vitro. Technol Cancer Res Treat 2008; 7:321-7. [DOI: 10.1177/153303460800700406] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
In cryosurgery it is crucial that the performance of cryoprobes is predictable and constant. In this study we tested the intra- and interneedle variation between 17-gauge cryoprobes in two homogeneous mediums. Also, a multiprobe setup was tested. Cryoprobe performance was defined as the time it takes one cryoprobe to lower the temperature from 0 to −20 °C as measured by four thermosensors each at 3 mm distance from the cryoprobe. In agar eight cryoprobes were tested during six freeze cycles, and in gel four cryoprobes during four freeze cycles; each freeze cycle in a different cup of agar or gel. Using more accurate ‘bare’ thermosensors three cryoprobes were tested in gel during two freeze cycles. A multiprobe configuration with four cryoprobes was tested during two freeze cycles in both agar and gel. Statistical analyses were done using ANOVA for repeated measures. There was no significant intraneedle variation, whereas both in agar and gel there was a significant interneedle variation (p<0.05). Mean performance in gel was better than in agar (p<0.001). Also, there was a significant variation between the four thermosensors (p< 0.001). Using bare thermosensors mean performance was 2.7 times faster compared to measurements by regular thermosensors (p<0.001). In a multiprobe configuration, overall performance seems less variable and more reproducible compared to a single cryoprobe. In conclusion, the performance of cryoprobes differs depending on the medium and measuring device used. Cryoprobes deliver reproducible freeze cycles, although there is variation between different cryoprobes. In a multiprobe configuration performance seems less variable.
Collapse
Affiliation(s)
- Patricia W.T. Beemster
- Department of Urology Academic Medical Center University of Amsterdam Meibergdreef 9 1105 AZ Amsterdam ZO The Netherlands
| | - Brunolf W. Lagerveld
- Department of Urology St. Lucas Andreas Hospital Jan Tooropstraat 164 1061 AE Amsterdam The Netherlands and Onze Lieve Vrouwen Gasthuis Oosterpark 9 1091 AC Amsterdam The Netherlands
| | - Lambertus P. W. Witte
- Department of Urology Academic Medical Center University of Amsterdam Meibergdreef 9 1105 AZ Amsterdam ZO The Netherlands
| | - Jean J. M. C. H. de la Rosette
- Department of Urology Academic Medical Center University of Amsterdam Meibergdreef 9 1105 AZ Amsterdam ZO The Netherlands
| | - M. Pilar Laguna Pes
- Department of Urology Academic Medical Center University of Amsterdam Meibergdreef 9 1105 AZ Amsterdam ZO The Netherlands
| | - Hessel Wijkstra
- Department of Urology Academic Medical Center University of Amsterdam Meibergdreef 9 1105 AZ Amsterdam ZO The Netherlands
| |
Collapse
|
4
|
Gowardhan B, Greene D. Cryotherapy for the prostate: an in vitro and clinical study of two new developments; advanced cryoneedles and a temperature monitoring system. BJU Int 2007; 100:295-302. [PMID: 17511766 DOI: 10.1111/j.1464-410x.2007.06983.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
OBJECTIVES To assess the characteristics of two new developments in cryotherapy for the prostate, IceRods (Oncura, Amersham, UK; 17 G cryoneedles with an advanced heat exchanger which produces a precise ice-ball comparable in size to those with larger diameter cryoneedles) and the Multitemp 1601 temperature monitoring system (TMS, InvivoSense, Trondheim, Norway) probes, in an in vitro model and in a clinical setting, to assess their usefulness, focusing in particular on the TMS probes. PATIENTS, MATERIALS AND METHODS We assessed the temperature profile and performance of the IceRods in several different configurations, in conjunction with the TMS probes for temperature mapping, in a phantom prostate model. Subsequently 20 patients with prostate cancer were treated with cryosurgery either as a primary or secondary treatment for radiation failure; all had a standard treatment protocol. The temperatures throughout the procedure were recorded accurately and analysed. RESULTS The IceRods were better able to freeze tissue, reaching lower temperatures than conventional cryoneedles. The IceRods were also capable of forming ice-balls with a maximum diameter of >6 cm after freezing at full power for 10 min. The TMS probes depicted real-time temperature gradients over either four or eight points in a linear array, enabling more thorough monitoring of the temperature changes during a treatment cycle. In the clinical setting, in all 20 patients, therapeutic freezing of <-40 degrees C was achieved in both the cycles. Temperatures of approximately - 40 degrees C were attained in the area just outside the prostate, as measured by the TMS probes, but with variation along the longitudinal axis. The rectal and external urinary sphincter temperatures did not fall below 0 degrees C at any of the points along the eight-point temperature probe, but there was variation in temperature along the prostate. CONCLUSION IceRods and the TMS probes are clinically useful, requiring fewer cryoneedles and with more efficient temperature monitoring; this would be expected to reduce morbidity and increase safety without compromising an adequate oncological outcome. The IceRods were useful in larger prostates of >3.5 cm long, which obviated the need for a 'pull-back' technique. The TMS probes showed convincingly the variation in temperatures along one line, suggesting that single-point temperature monitoring might not accurately depict the lowest temperatures reached during treatment, which is particularly important in the rectum. This is a significant development in cryosurgery and would make the procedure safer, reproducible and allow interested clinicians to learn the technique safely and more quickly.
Collapse
Affiliation(s)
- Bharat Gowardhan
- Department of Urology, Sunderland Royal Hospital, Sunderland, UK
| | | |
Collapse
|
5
|
Popken F, Seifert JK, Engelmann R, Dutkowski P, Nassir F, Junginger T. Comparison of iceball diameter and temperature distribution achieved with 3-mm accuprobe cryoprobes in porcine and human liver tissue and human colorectal liver metastases in vitro. Cryobiology 2000; 40:302-10. [PMID: 10924262 DOI: 10.1006/cryo.2000.2250] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
We aimed to assess the thermal profile and size of iceballs produced by Accuprobe cryoprobes in fresh porcine and human liver and human colorectal cancer liver metastases in vitro to allow better planning of cryosurgical treatment of liver metastases. Iceballs were produced by a 20-min single freeze cycle using 8-mm cryoprobes in pig liver in a waterbath at 37 degrees C (n = 8) and 3-mm cryoprobes in pig liver (n = 8), human liver (n = 3), and human colorectal cancer liver metastases (n = 8). The iceball diameters and the temperatures at different distances from the cryoprobe were measured. Mean iceball diameters produced by 8-mm cryoprobes in pig liver were 56.3 mm and varied from 38.7 to 39.6 mm for 3-mm cryoprobes in the different tissues used. There was no significant difference in iceball size in the different tissues. The diameter of the zone of -40 degrees C or less was approximately 44 mm using 8-mm cryoprobes in porcine liver and between 27 and 31 mm using 3-mm cryoprobes in the different tissues examined. The results may allow better preoperative planning of the cryosurgical treatment of liver metastases with Accuprobe cryoprobes.
Collapse
Affiliation(s)
- F Popken
- Klinik für Allgemein- und Abdominalchirurgie, der Johannes Gutenberg-Universität, Langenbeckstr, 1, Mainz, 55101, Germany
| | | | | | | | | | | |
Collapse
|
6
|
Abstract
Hepatic cryotherapy has emerged as a viable therapeutic option in the treatment of liver tumors, both primary and secondary. We will provide the experimental basis for its application in the liver with particular reference to safety and efficacy issues. Also discussed are experiments with the use of hepatic cryotherapy in animals that have demonstrated the effectiveness of the technique, and improvements in technology that have enabled better delivery. The future of this modality looks bright with increasing advances in technology to enable better application. Its use in combination with other treatment modalities could offer improved success in treating liver tumors.
Collapse
Affiliation(s)
- B A Mascarenhas
- Department of Surgery, Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick 08901, USA
| | | |
Collapse
|
7
|
Abstract
Percutaneous transperineal cryoablation of the prostate is now available in the armamentarium for treatment of prostate cancer. Technical advances in real-time transrectal imaging of the prostate and improvements in cryosurgical equipment have brought this modality into the limelight of available prostate cancer management. Cryosurgery can be offered to many patients with prostate cancer. However, the main indications for its use include primary treatment for localized disease, salvage therapy after failure of traditional methods, and relief of local symptoms. A historical background, description of the technique, and clinical experience at several medical centers including the University of California San Diego, Allegheny General Hospital, University of Texas M.D. Anderson Cancer Center, and Crittenton Hospital, are presented.
Collapse
Affiliation(s)
- B G Patel
- Division of Urology, UCSD Medical Center 92103-8897, USA
| | | | | | | |
Collapse
|
8
|
Long JP. Is there a role for cryoablation of the prostate in the management of localized prostate carcinoma? Hematol Oncol Clin North Am 1996; 10:675-90. [PMID: 8773504 DOI: 10.1016/s0889-8588(05)70360-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
It is impossible to adequately answer the question of whether there is a role for CSAP in the management of localized prostate carcinoma without considering the relative advantages and limitations of using other therapies to manage this disease (radical prostatectomy, radiation therapy, hormonal therapy, brachytherapy, expectant observation, and so on). Obviously, this is beyond the scope of this article. It is probably fair to point out, however, that the management of localized prostate carcinoma in the United States is generally quite controversial at the present time, and that despite a considerable amount of data pertaining to these therapeutic alternatives, it is difficult to discern a standard approach that can be broadly applied for all men with this disease. Therefore, if an absence of consensus on the management of localized prostate carcinoma does exist, it seems evident that investigations into alternative therapies are justified, and the preliminary results and efforts investigating CSAP fall well into this paradigm. In this context, several points can be made based on the available information. Significant numbers of patients who undergo CSAP can sustain undetectable levels of PSA for durable periods of time (more than 24 months). Thus, on a clinical level it seems possible to ablate the entire prostate with percutaneous CSAP, although rates of achieving this may be lower than originally anticipated. The reasons for persistence of carcinoma post CSAP are likely technical and related to the difficulties in determining the effective probe placements, number of probes to be used, number of freeze-thaw-freeze cycles to be used, and so on. Previous radiation exposure appears to confer an increased risk of CSAP-related morbidity, with incontinence, tissue sloughing, and rectal injury most prominent. Among nonradiated patients, incontinence is rare, and the most prominent postoperative concern involves BOO/tissue sloughing in a minority of patients. The longest follow-up data available on CSAP suggests that for patients with nonmetastatic prostate carcinoma, CSAP is associated with persistence of carcinoma in only 25% of patients. This compares favorably with the available biopsy data following external beam radiotherapy, in which most reports document positive biopsy results ranging between 30% and 100%, with the majority in the 40% to 50% range. Notably, the positive biopsy rate among patients with stage T3 disease following CSAP at 2 years can be less than 30%, which compares very favorably with previously reported positive biopsy result for these patients following external beam radiation therapy, which ranged between 40% and 100%. The management of patients with persistent carcinoma following CSAP poses fewer concerns to physicians than for those with persistent carcinoma following radiation therapy. Given the number of patients with prostate carcinoma who currently undergo radiotherapy as primary management, these data indicate that CSAP can now be considered a very viable therapeutic alternative for selected patients. With standardizations of technique as well as improved modifications in equipment, these preliminary CSAP results may well improve steadily in the near future. In the absence of randomized, comparative trials, it is difficult to draw meaningful comparisons between CSAP and radical prostatectomy. Based on available information, CSAP appears to be associated with a much lower incidence of stress and total incontinence than is radical prostatectomy. The rates of impotence following CSAP are somewhat comparable to those seen after radical prostatectomy, with wide variation among individual series. For patients who would be ideal candidates for radical prostatectomy (for example, less than stage T2c disease, PSA less than 10 ng/mL, and Gleason score of 7 or less), several authors have noted that the positive biopsy rate between 6 and 12 months is less than 10%.
Collapse
Affiliation(s)
- J P Long
- Department of Urology, Tufts University School of Medicine, Boston, Massachusetts, USA
| |
Collapse
|
9
|
Editorial. J Urol 1995. [DOI: 10.1097/00005392-199508000-00031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
10
|
|